Nektar Therapeutics (NKTR) Stock Analysis

Nektar Therapeutics (NKTR) is a publicly traded company in the HEALTHCARE sector. It trades at $58.56, carries a market capitalization of $2.19B. This page summarizes the public market data, fundamentals, and frequently asked questions for NKTR, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Nektar Therapeutics currently has a Neutral sentiment score of 0.10.

About Nektar Therapeutics

Nektar Therapeutics is a San Francisco-based biopharmaceutical company dedicated to the discovery and development of innovative therapies for significant unmet medical needs across diverse disease areas, including cancer, autoimmune disorders, and chronic pain. The company boasts a robust clinical pipeline and utilizes proprietary drug development technologies designed to improve both the efficacy and safety profiles of its therapeutics. With additional operational facilities in Huntsville, A...

GNG Research Analysis

GNG Research scores Nektar Therapeutics (NKTR) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for NKTR.

Frequently Asked Questions

Does NKTR pay dividends?

Nektar Therapeutics (NKTR) does not currently pay a regular dividend.

What is NKTR's market cap?

Nektar Therapeutics (NKTR) has a market capitalization of $2.19B with a current stock price of $58.56.